The medication is commonly used across therapeutic domains where its antimicrobial activity is applicable. It is generally applied when supportive management is needed in specific contexts of bacterial disease.

Sword is considered relevant in conditions characterized by periods of heightened symptoms, including infections of the lower urinary tract (UTIs, prostatitis), acute exacerbation of chronic bronchitis (AECB), acute bacterial rhinosinusitis, and certain infectious diarrheas like traveler's diarrhea.

It is applied in scenarios where additional management of discomfort is required, especially when symptoms related to inflammatory or irritative states interfere with daily functioning.

---

Quick Fact: Relief for Acute Discomfort

A key benefit is that the medication supports the management of the underlying condition, which generally contributes to easing day-to-day comfort during symptomatic periods. This provides supportive relief that helps manage the symptom load in conditions presenting with systemic or localized discomfort. Sword is often used during phases when symptoms become more noticeable and short-term symptomatic assistance is needed.

Eligibility for Sword (Prulifloxacin)

Sword is an antibiotic approved only for use in adult patients (18 years and older).

---

Populations for Whom Use is Contraindicated

Use of Prulifloxacin is strictly prohibited (contraindicated) in several patient groups, as defined in official labeling:

• Pediatric Population: Children and adolescents under 18 years of age.
• Hypersensitivity: Patients with known allergy to Prulifloxacin or any other quinolone class antibiotic.
• Tendon History: Individuals with a history of tendon disorders (e.g., tendinitis or rupture) related to prior fluoroquinolone use.
• Neurological Conditions: Patients with epilepsy or a history of seizure disorders.
• Reproductive Status: Women who are pregnant or breastfeeding.

---

Populations with Restricted or Conditional Use

Use requires caution in the following groups due to specific risks associated with this class of medicine:

• Older Adults: Increased risk of tendon disorders, especially when taking systemic corticosteroids concurrently.
• Renal Impairment: Not generally recommended in cases of severe kidney impairment (Creatinine Clearance < 30 mL/min).
• Comorbidities: Patients with a known risk of QT interval prolongation or Myasthenia Gravis.

Interactions with other medicines and products

Sword (Prulifloxacin) interacts with several medicinal products and substance categories, primarily through mechanisms that alter drug exposure or result in heightened pharmacodynamic risks, as documented in regulatory information.

Interaction Scope

Interaction Type	Interacting Substance/Category	Official Restriction or Outcome
Absorption Interference	Multivalent Cation-Containing Products (e.g., antacids, iron supplements, calcium preparations)	Co-administration reduces the absorption of Prulifloxacin, necessitating a timing separation rule.
Decreased Clearance	Theophylline	Co-administration results in decreased clearance of Theophylline, requiring monitoring of plasma levels.
Pharmacodynamic Augmentation	Fenbufen (NSAID)	Increased risk of convulsions is documented.
Pharmacodynamic Augmentation	Systemic Corticosteroids	Avoided due to significantly increased risk of tendinitis and tendon rupture, particularly in older patients.
Pharmacodynamic Augmentation	Oral Anticoagulants (e.g., Warfarin)	Enhances the effect of the anticoagulant, requiring coagulation monitoring.
Pharmacodynamic Augmentation	Drugs that Prolong the QT Interval	Not recommended due to increased risk of QTc prolongation.

Timing-Based Administration Rules

To prevent the loss of antibiotic effectiveness due to absorption interference, regulatory documents mandate that Sword must be administered 2 hours before or at least 4 hours after the administration of multivalent cation-containing products like antacids, Cimetidine, or preparations containing iron and calcium.

Population-Specific Notes

The interaction risk leading to potential hypoglycemia is noted for diabetic patients concurrently treated with hypoglycemic agents.

Targeting Core Bacterial Genetic Machinery

The mechanism of Sword relies on its active form, ulifloxacin, directly targeting two essential bacterial enzymes: DNA Gyrase and Topoisomerase IV. Ulifloxacin operates as a molecular inhibitor, binding to these enzymes while they are attached to the bacterial DNA, thereby poisoning them and preventing the re-ligation of cut DNA strands. This action blocks the function of the pathogen's core genetic machinery.

---

Triggering Catastrophic Bactericidal Cascade

The molecular inhibition triggers a rapid mechanistic cascade resulting in the accumulation of irreversible, lethal double-strand DNA breaks inside the bacteria. This widespread genetic damage blocks the pathogen’s ability to replicate, transcribe, or repair itself, initiating a process that culminates in bactericidal cell death. The physiological consequence of this cellular destruction is a systemic decrease in the population of susceptible bacterial cells.

---

Pathway Limitations and Resistance Mechanisms

The mechanism is constrained by specific biological limitations developed by bacteria. These include genetic mutations in the target enzymes (DNA Gyrase/Topoisomerase IV) that reduce drug binding affinity, or the activation of bacterial efflux pumps that actively expel ulifloxacin from the cell. Such biological adaptations reduce the molecule's concentration or binding affinity at the target site.

Administration Principles and Dosage

Sword (Prulifloxacin) is formally designated as an oral tablet used for systemic administration. The standard administration pattern is once daily (q.d.), which ensures consistent drug levels throughout the prescribed course. The tablet must be taken whole and swallowed with water; it should not be crushed, split, or chewed. The typical prescribed dose is 600 mg per day for most approved usage patterns.

---

Course Duration and Timing Constraints

The required length of treatment is subject to the specific condition, following short-course therapy principles that range from a single 600 mg dose for uncomplicated infections up to a maximum duration of 10 days for other approved indications. If a dose is missed, the standard protocol is to take it as soon as it is remembered on that same day, unless the next scheduled dose is imminent, in which case the regimen is resumed without taking the skipped amount. Double dosing is prohibited under all circumstances.

---

Procedural and Population Adjustments

Specific procedural constraints are mandated to optimize absorption. The tablet must be taken 2 to 4 hours apart from the consumption of any products containing multivalent cations, which include antacids, iron supplements, and calcium-fortified beverages. While the drug can be taken with or without food, this timing separation is a critical use requirement. Usage is generally established for adults, and a high-level adjustment to 300 mg once daily is required for patients who have severe renal impairment (creatinine clearance below 30 mL/min).

Research Evidence / Overview of Studies for Sword (Prulifloxacin)

Evidence for Use in Complicated Lower Urinary Tract Infections (cUTIs)

The available research for Sword's evaluation in complicated lower urinary tract infections includes Phase III Randomized Controlled Trials (RCTs) and comparative studies. These studies were structured to compare Sword against other agents and were conducted in adult patients whose infections often involve underlying urological issues. Researchers monitored outcomes, including the degree of bacterial clearance from the body (microbiological eradication rate) and the overall clinical outcome. Findings describe patterns of symptom resolution in the observed populations. However, due to the complexity of defining cUTIs, the results apply only to the specific populations studied, and long-term follow-up beyond the short period is not consistently characterized in the main trial data.

Evidence for Use in Acute Exacerbation of Chronic Bronchitis (AECB)

Research for Sword's evaluation in flare-ups of chronic bronchitis also includes Randomized Controlled Trials (RCTs) and observational studies. These research scenarios explored short-term symptom changes in adult patients with established COPD experiencing a period of increased symptom activity. Studies monitored outcomes related to physical discomfort, examining the degree of bacterial clearance and tracking changes measured during the study period, categorized as clinical success. The results apply mainly to non-hospitalized AECB cases, and data for severely ill patients who may require intensive care is limited. Sustained reduction in the frequency of future flare-ups is not well characterized.

Evidence in Special Populations and Uncertainties

Sword was also evaluated in studies for Chronic Bacterial Prostatitis (CBP) and infectious diarrheas, where the study of microbiological eradication and symptom monitoring was explored. For these conditions, sample sizes were often modest, and the evidence quality varies across studies. Across all indications, data for long-term follow-up remain limited for most outcomes. Comparative evidence is often lacking for specific patient subgroups with multiple complex comorbidities, and research does not determine whether an individual will respond similarly to the group patterns observed in trials.

Common questions about Sword (FAQ)

Q: Is Sword considered a first-line treatment for its primary indication?

Due to the potential risk of serious side effects associated with the fluoroquinolone class, regulatory bodies indicate that the use of this medicine is generally reserved. Official documents describe that its use is recommended for situations where other commonly indicated antibiotics or alternative treatments are not suitable.

---

Q: Does Sword have the potential to cause changes in mood or behavior?

Official safety warnings for this class of medicine confirm documented risks of mental health side effects. These can include feelings of nervousness, agitation, anxiety, memory impairment, confusion, and delirium. This information is included in the official prescribing documents.

---

Q: Can taking certain vitamins or herbal supplements affect how Sword works?

Regulatory information emphasizes that co-administration with products containing multivalent cations (such as iron or calcium supplements) necessitates a timing separation protocol. This protocol is in place because these cations can significantly decrease the drug's absorption. Specific details on the interaction of all herbal supplements are not universally included in the official prescribing documents.

---

Q: How quickly should a patient expect to feel the effects of Sword?

According to pharmacokinetic studies, the medicine is rapidly absorbed after ingestion. It is converted into its active therapeutic form, ulifloxacin, which typically reaches its maximum concentration in the blood about two hours after administration.

---

Q: How long does the active ingredient of Sword stay in the body after the last dose?

The active compound, ulifloxacin, is known to have a long elimination half-life. This extended presence in the body is what permits the medicine to be described for once-daily dosing.

---

Q: What pre-existing health issues (like kidney or liver problems) are listed as contraindications for Sword?

Official documents state that use is contraindicated if there is a known allergy to the drug class, a history of quinolone-related tendon problems, or a history of epilepsy/seizure disorders. For severe kidney impairment, a high-level adjustment to the prescribed amount is noted in official guidance. Furthermore, the safety and effectiveness for patients with severe liver impairment have not been formally evaluated.

---

Q: Does Sword require any routine blood tests or monitoring while a patient is taking it?

Routine blood tests are not generally required for all patients taking the medicine. However, specific laboratory monitoring is mandated by official documents when the drug is taken alongside certain other medicines. For instance, official documents note the need for monitoring of coagulation levels for concurrent use with blood thinners.

---

Q: What are the non-active ingredients or excipients contained in the Sword tablet/capsule?

The full composition of the tablet, including all non-active ingredients (called excipients), is detailed in the official prescribing information. Regulatory agencies require this complete list to be included in the product information.

---

Q: What activities, such as driving or operating heavy machinery, are officially restricted while taking Sword?

Because the drug is associated with adverse effects on the nervous system, such as dizziness, confusion, and other mental disturbances, official guidance advises caution. Documents indicate that activities requiring complete mental alertness, such as driving or operating heavy machinery, may need to be avoided until the individual knows how the drug affects them.

---

Q: What is the mechanism by which the body breaks down and eliminates Sword?

The medicine is considered a prodrug, which means it is an inactive form that is rapidly changed by the body's natural metabolic processes into its potent, active component, ulifloxacin. The active compound is then gradually eliminated from the body, and its long half-life supports once-daily dosing.

---

Q: Are there any specific dietary restrictions or food interactions mentioned for Sword?

Official information confirms a number of restrictions. Official guidelines require separation protocols for the tablet's administration relative to products containing multivalent cations like iron and calcium. Furthermore, the co-ingestion of milk is specifically noted in regulatory information to reduce the drug's absorption and elimination.

---

Q: Is it true that certain official documents describe a possible risk of sun sensitivity with Sword?

Yes, the official regulatory safety documents for this medicine describe phototoxicity as a documented, though rare, adverse effect. Phototoxicity refers to a severe reaction that can occur on the skin following exposure to sunlight or UV light.

---

Q: Does the official information for Sword mention any impact on appetite or weight changes?

Yes, official information for this medicine documents an impact on appetite as an adverse effect. Specifically, anorexia (a loss of appetite) has been documented in official regulatory listings, categorized as an uncommon effect.

---

Q: How is the safety of Sword tracked and monitored after it has been released to the public?

Like all medicines approved by regulatory bodies, Sword is subject to continuous safety surveillance. This process is known as pharmacovigilance, where new safety information is collected and tracked once the medicine is available for use by the general public.

Official Storage and Disposal Requirements

The storage and disposal instructions for Sword are defined by government regulatory documents to ensure product stability and public safety. These instructions must be strictly followed.

Storage Conditions

Requirement Category	Official Statement
Temperature Range	Store at controlled room temperature, typically between 20°C and 25°C.
Protection Rules	Keep in the original container to protect the medicine from light and moisture.
Prohibited Storage	Do not freeze or store above the maximum stated temperature (e.g., 25°C or 30°C).
Child Safety	Keep the medicine out of the sight and reach of children.

Disposal and Stability

If the product requires mixing or is opened, note the in-use stability period; the product must be used or discarded within the defined timeframe (e.g., 24 hours). For disposal of expired or unused product, consult official label instructions, which typically recommend utilizing a drug take-back program or following federal guidance for safe home disposal to prevent environmental release.